RecruitingPHASE2, PHASE3NCT06988475
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cancer Research UK
- Principal Investigator
- Matthew Krebs, DrThe Christie Hospital
- Intervention
- Capmatinib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (17)
- Belfast City Hospital, Belfast, United Kingdom
- University Hospital Birmingham, Birmingham, United Kingdom
- Bristol Haematology and Oncology Centre, Bristol, United Kingdom
- Addenbrooke's Hospital, Cambridge, United Kingdom
- Velindre Cancer Centre, Cardiff, United Kingdom
- Western General Hospital, Edinburgh, United Kingdom
- The Beatson Hospital, Glasgow, United Kingdom
- Leicester Royal Infirmary, Leicester, United Kingdom
- University College London Hospital, London, United Kingdom
- Guy's Hospital, London, United Kingdom
- The Christie Hospital, Manchester, United Kingdom
- Clatterbridge Cancer Centre, Metropolitan Borough of Wirral, United Kingdom
- Freeman Hospital, Newcastle, United Kingdom
- Churchill Hospital, Oxford, United Kingdom
- Western Park Hospital, Sheffield, United Kingdom
- +2 more locations on ClinicalTrials.gov
Collaborators
University of Birmingham · Royal Marsden NHS Foundation Trust · Novartis Pharmaceuticals · University of Manchester
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06988475 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University